Protease-activated receptors as targets for antiplatelet therapy

Blood Reviews

Volumn 23, Issue 2, 2009, Pages 61-65

  Hamilton, Justin R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Antiplatelet agents; Arterial thrombosis; Platelets; Protease activated receptors; Thrombin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR; THROMBIN; TIROFIBAN;

ACUTE HEART INFARCTION; ARTERY THROMBOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG INHIBITION; FIBRIN FORMATION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PROTEINASE-ACTIVATED; THROMBOSIS;

EID: 60849087332     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.06.002     Document Type: Article

References (42)

1. Heart Disease and Stroke Statistics: 2006 update. Dallas, USA: American Heart Association; 2006.
2. World Health Report 2002. Geneva, Switzerland: World Health Organisation; 2002.
3. Antithrombotic triallists collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002;324:71-86.
4. Tran H.A., Anand S.S., Hankey G.J., and Eikelboom J.W. Aspirin resistance. Thromb Res 120 (2007) 337-346
5. Gurbel P.A., and Tantry U.S. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19 (2006) 439-448
6. Gladding P., Webster M., Ormiston J., Olsen S., and White H. Antiplatelet drug nonresponsiveness. Am Heart J 155 (2008) 591-599
7. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
8. Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. Advance online publication, 5 March 2008. doi:10.1038/jcbfm.2008.9.
9. Coma-Canella I., and Velasc A. Variability in individual responsiveness to aspirin: clinical implications and treatment. Cardiovasc Hematol Disord Drug Targets 7 (2007) 274-287
10. Patel D., and Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther 5 (2007) 969-975
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
12. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med 354 (2006) 1706-1717
13. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
14. Karvouni E., Katritsis D.G., and Ioannidis J.P. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 41 (2003) 26-32
15. Sane D.C., Damaraju L.V., Topol E.J., et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36 (2000) 75-83
16. Chew D.P., Bhatt D.L., Sapp S., and Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 (2001) 201-206
17. Furie B., and Furie B.C. Thrombus formation in vivo. J Clin Invest 115 (2005) 3355-3362
18. Brass L.F. Thrombus formation: stability matters. Blood 108 (2006) 2883-2884
19. Hamilton J.R., Kaplan Z., Jackson S.P., and Opat S. Antiplatelet therapy: current status & future prospects. Expert Opin Drug Discov 2 (2007) 1-6
20. Savage B., Saldivar E., and Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84 (1996) 289-297
21. Kato K., Kanaji T., Russell S., et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 102 (2003) 1701-1707
22. Denis C.V., and Wagner D.D. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 27 (2007) 728-739
23. Brass L.F., Jiang H., Wu J., Stalker T.J., and Zhu L. Contact-dependent signaling events that promote thrombus formation. Blood Cells Mol Dis 36 (2006) 157-161
24. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 407 (2000) 258-264
25. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103 (1999) 879-887
26. Jackson S.P. The growing complexity of platelet aggregation. Blood 109 (2007) 5087-5095
27. Kahn M.L., Zheng Y.-W., Huang W., et al. A dual thrombin receptor system for platelet activation. Nature 394 (1998) 690-694
28. Nakanishi-Matsui M., Zheng Y.W., Sulciner D.J., Weiss E.J., Ludeman M.J., and Coughlin S.R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404 (2000) 609-613
29. Sambrano G.R., Weiss E.J., Zheng Y.W., Huang W., and Coughlin S.R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413 (2001) 74-78
30. Hamilton J.R., Cornelissen I., and Coughlin S.R. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2 (2004) 1429-1435
31. Vandendries E.R., Hamilton J.R., Coughlin S.R., Furie B., and Furie B.C. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA 104 (2007) 288-292
32. Camerer E., Duong D.N., Hamilton J.R., and Coughlin S.R. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood 103 (2004) 152-154
33. Ishihara H., Zeng D., Connolly A.J., Tam C., and Coughlin S.R. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood 91 (1998) 4152-4157
34. Weiss E.J., Hamilton J.R., Lease K.E., and Coughlin S.R. Protection against thrombosis in mice lacking PAR3. Blood 100 (2002) 3240-3244
35. Cook J.J., Sitko G.R., Bednar B., et al. An antibody against the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91 (1995) 2961-2971
36. Derian C.K., Damiano B.P., Addo M.F., et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304 (2003) 855-861
37. Vu T.-K.H., Hung D.T., Wheaton V.I., and Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 (1991) 1057-1068
38. Coughlin S.R., Vu T.-K.H., Hung D.T., and Wheaton V.I. Characterization of a functional thrombin receptor. J Clin Invest 89 (1992) 351-355
39. Chackalamannil S., Xia Y., Greenlee W.J., et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 48 (2005) 5884-5887
40. Chelliah M.V., Chackalamannil S., Xia Y., et al. Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists. J Med Chem 50 (2007) 5147-5160
41. Schering-Plough announces initiation of two phase III clinical trials for novel selective antiplatelet therapy (TRA-SCH 530348); 2007. .
42. A double-blind study of E5555 in Japanese patients with acute coronary syndrome; 2008. .